Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (62,796)	$ (40,642)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	4,637	2,252
Noncash lease expense	1,792	1,732
Share-based compensation expense	12,861	8,484
Intangible assets amortization	419	419
Investment amortization	862	2,108
Other	(20)	(9)
Changes in operating assets and liabilities
Accounts receivable, net	(5,109)	(9,707)
Inventory	(1,739)	(3,359)
Prepaid expenses and other current assets	962	1,273
Accounts payable and accrued liabilities	(7,545)	(7,257)
Operating lease right-of-use assets and liabilities	2,035	813
Deferred revenue	(10,812)	(14,233)
Other		(119)
Net cash used in operating activities	(64,453)	(58,245)
Investing activities
Purchases of property and equipment	(3,077)	(15,841)
Purchases of marketable securities	(60,235)	(15,340)
Proceeds from maturities of marketable securities	101,000	125,000
Net cash provided by investing activities	37,688	93,819
Financing activities
Proceeds from exercise of stock options	2,749	14,185
Proceeds from initial capital contributions for Digital Biotechnologies, Inc.		429
Net cash provided by financing activities	2,749	14,614
Net (decrease) increase in cash, cash equivalents and restricted cash	(24,016)	50,188
Cash, cash equivalents and restricted cash at beginning of year	141,203	125,574
Cash, cash equivalents and restricted cash at end of period	117,187	175,762
Noncash investing activities
Purchases of equipment included in accounts payable and accrued liabilities	$ 2,952	$ 7,698